![Louis St. Laurence O'Dea](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Louis St. Laurence O'Dea
Former positions of Louis St. Laurence O'Dea
Companies | Position | Start | End |
---|---|---|---|
AKCEA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2015-12-31 | 2020-07-06 |
OXFORD IMMUNOTEC GLOBAL PLC | Chief Tech/Sci/R&D Officer | 2014-06-06 | 2015-12-31 |
MODERNA, INC. | Chief Tech/Sci/R&D Officer | 2011-12-31 | 2014-05-31 |
RADIUS HEALTH, INC. | Chief Tech/Sci/R&D Officer | 2006-02-28 | - |
Serono Corp. | Corporate Officer/Principal | 2000-06-30 | 2005-12-31 |
Training of Louis St. Laurence O'Dea
University College Dublin | Doctorate Degree |
Statistics
International
United States | 4 |
Ireland | 2 |
Israel | 2 |
Operational
Chief Tech/Sci/R&D Officer | 4 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
MODERNA, INC. | Health Technology |
Private companies | 4 |
---|---|
Radius Health, Inc.
![]() Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Serono Corp. | |
Oxford Immunotec Global Ltd.
![]() Oxford Immunotec Global Ltd. Medical SpecialtiesHealth Technology Oxford Immunotec Global Ltd. operates as a diagnostics company, which develops and commercializes proprietary tests for immunology and infectious disease. Its products include T-SPOT.TB, T-SPOT.CMV, T-SPOT.PRT and T-CELL XTEND. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Akcea Therapeutics, Inc.
![]() Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |